FDA disrupts Harmony's expansion dreams for excessive sleepiness drug Wakix with refusal letter
The agency responded to Harmony's bid for an idiopathic hypersomnia nod for excessive daytime sleepiness med Wakix with a refusal to file letter after a missed phase 3 study.
The agency responded to Harmony's bid for an idiopathic hypersomnia nod for excessive daytime sleepiness med Wakix with a refusal to file letter after a missed phase 3 study.
